Neumann, Avidan U.

Publishing since 1995 (Senior)

Has published 68 publications in 16 years

Number of publications published per year by Neumann, Avidan U.. (Source : PubMed)

Distribution of publications types for Neumann, Avidan U.. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Feld JJ, Lutchman GA, Heller T, Hara K, Pfeiffer JK, Leff RD, Meek C, Rivera M, Ko M, Koh C, Rotman Y, Ghany MG, Haynes-Williams V, Neumann AU, Liang TJ, Hoofnagle JH. Ribavirin improves early responses to peginterferon through enhanced interferon signaling.  Gastroenterology  2010  
•  Lukasiewicz E, Gorfine M, Neumann AU, Freedman LS. Combining longitudinal discriminant analysis and partial area under the ROC curve to predict non-response to treatment for hepatitis C virus.  Stat Methods Med Res  2010  
•  Rotman Y, Borg BB, Soza A, Feld JJ, Modi AA, Loomba R, Lutchman G, Rivera E, Doo E, Ghany MG, Heller T, Neumann AU, Liang TJ, Hoofnagle JH. Clinical trial: low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3 - efficacy, tolerability, viral kinetics and cytokine response.  Aliment. Pharmacol. Ther.  2010  
•  Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.  Hepatology  2009  
•  Rozenberg L, Haagmans BL, Neumann AU, Chen G, McLaughlin M, Levy-Drummer RS, Masur H, Dewar RL, Ferenci P, Silva M, Viola MS, Polis MA, Kottilil S. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.  AIDS  2009;23;18  
•  Neumann AU, Bain VG, Yoshida EM, Patel K, Pulkstenis E, Subramanian GM. Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C.  Liver Int.  2009;29;9  
•  Lukasiewicz E, Gorfine M, Freedman LS, Pawlotsky JM, Schalm SW, Ferrari C, Zeuzem S, Neumann AU. Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment.  J. Viral Hepat.  2009  
•  Jain MK, Yuan HJ, Adams-Huet B, Reeck A, Shelton J, Attar N, Zhang S, Neumann AU, Carney DS, Gale M, Lee WM. Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.  J. Infect. Dis.  2009;200;6  
•  Neumann AU, Pianko S, Zeuzem S, Yoshida EM, Benhamou Y, Mishan M, McHutchison JG, Pulkstenis E, Mani Subramanian G. Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.  J. Hepatol.  2009;51;1  
•  Adiwijaya BS, Hare B, Caron PR, Randle JC, Neumann AU, Reesink HW, Zeuzem S, Herrmann E. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment.  Antivir. Ther. (Lond.)  2009;14;4  

[ See timeline ] [ See all publications ]